Conditional Deletion of Men1 in the Pancreatic β-Cell Leads to Glucagon-Expressing Tumor Development
Author(s) -
Feng Li,
Yutong Su,
Yulong Cheng,
Xiuli Jiang,
Ying Peng,
Yanli Li,
Jieli Lu,
Yanyun Gu,
Chang Zhang,
Yanan Cao,
Weiqing Wang,
Guang Ning
Publication year - 2014
Publication title -
endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.674
H-Index - 257
eISSN - 1945-7170
pISSN - 0013-7227
DOI - 10.1210/en.2014-1433
Subject(s) - men1 , biology , carcinogenesis , transcription factor , cancer research , endocrinology , medicine , cre recombinase , glucagon , cell growth , pancreas , pdx1 , oncogene , cell , microbiology and biotechnology , islet , cell cycle , insulin , gene , genetics , transgene , hormone , endocrine system , genetically modified mouse
The tumor suppressor menin is recognized as a key regulator of β-cell proliferation. To induce tumorigenesis within the pancreatic β-cells, floxed alleles of Men1 were selectively ablated using Cre-recombinase driven by the insulin promoter. Despite the β-cell specificity of the RipCre, glucagon-expressing tumors as well as insulinomas developed in old mutant mice. These glucagon-expressing tumor cells were menin deficient and expressed the mature α-cell-specific transcription factors Brain-specific homeobox POU domain protein 4 (Brn4) and v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (MafB). Moreover, the inactivation of β-cell-specific transcription factors was observed in mutant β-cells. Our work shows that Men1 ablation in the pancreatic β-cells leads to the inactivation of specific transcription factors, resulting in glucagon-expressing tumor development, which sheds light on the mechanisms of islet tumorigenesis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom